Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
67 hedge funds and large institutions have $34.7M invested in Checkpoint Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 16 reducing their positions, and 16 closing their positions.
120% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $498K
31% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 16
7% more capital invested
Capital invested by funds: $32.3M → $34.7M (+$2.36M)
0.13% less ownership
Funds ownership: 1.52% → 1.4% (-0.13%)
3% less funds holding
Funds holding: 69 → 67 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$425K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$405K |
| 3 |
Two Sigma Advisers
New York
|
+$347K |
| 4 |
BlackRock
New York
|
+$332K |
| 5 |
Two Sigma Investments
New York
|
+$297K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$1.04M |
| 2 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$605K |
| 3 |
Millennium Management
New York
|
-$553K |
| 4 |
E
Ergoteles
New York
|
-$466K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$398K |
CKPT Hedge Fund Activity: Q3 2021 in Review
67 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q3 2021, worth a combined $34.7M — up 7.3% from $32.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CKPT and 14 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 21 added.
The largest buyer was Vanguard Group, adding an estimated $425K. The largest seller was Frontier Wealth Management, exiting entirely with an estimated $1.04M sold.
- 67 institutional investors held Checkpoint Therapeutics (CKPT) as of Q3 2021, down from 69 in Q2 2021.
- Funds reported $34.7M of Checkpoint Therapeutics stock for Q3 2021, up 7.3% quarter-over-quarter.
- 14 funds opened new Checkpoint Therapeutics positions in Q3 2021 and 16 closed out, a net change of -2 holders.
- The largest Checkpoint Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $425K added.
- The largest Checkpoint Therapeutics seller in Q3 2021 was Frontier Wealth Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q3 2021.